Drug Type Small molecule drug |
Synonyms Dapagliflozin/Saxagliptin/Metformin hydrochloride, Metformin Hydrochloride/Saxagliptin/Dapagliflozin, metformin hydrochloride/Saxagliptin/dapagliflozin + [2] |
Target |
Action inhibitors, activators |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors), PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators), SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseWithdrawn |
First Approval Date United States (02 May 2019), |
Regulation- |
Molecular FormulaC24H35ClO9 |
InChIKeyGOADIQFWSVMMRJ-UPGAGZFNSA-N |
CAS Registry960404-48-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Phase 2 | United States | 02 May 2019 |